TickerFacts.

Jade Biosciences, Inc. (JBIO): Capital Expenditures

Annual figures by period end, from SEC filings.

$196.0K
Year ended 2025-12-31
+0.2%
3-year compound annual growth
2021-12-31: $181.0K2022-12-31: $195.0K2023-12-31: $142.0K2025-12-31: $196.0K$196.0K
2021-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$196.0Kn/a2026-03-06, From 2025-01-01
No annual figure between 2023-12-31 and 2025-12-31.
2023-12-31$142.0K-27.2%2025-03-27, From 2023-01-01
2022-12-31$195.0K+7.7%2024-03-25, From 2022-01-01
2021-12-31$181.0Kn/a2023-03-29, From 2021-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Jade Biosciences, Inc. (JBIO)2025-12-31$196.0Kn/a
Zymeworks Inc. (ZYME)2025-12-31$1.52M-23.6%
Upstream Bio, Inc. (UPB)2025-12-31$165.0K-67.7%
Capricor Therapeutics, Inc. (CAPR)2025-12-31$2.90M+148.9%
Lyell Immunopharma, Inc. (LYEL)2025-12-31$780.0K+68.1%
Keros Therapeutics, Inc. (KROS)2025-12-31$1.55M-19.7%
Anaptysbio, Inc (ANAB)2025-12-31$87.0K-75.7%
Fulcrum Therapeutics, Inc. (FULC)2025-12-31$314.0K+12.9%
Amylyx Pharmaceuticals, Inc. (AMLX)2025-12-31$138.0K-12.1%

Compare JBIO, ZYME, UPB, CAPR side by side · Screen every company in Pharmaceutical Preparations ↗